Elutia Inc.

What they do

Elutia develops and markets proprietary biologic matrix products used in plastic, reconstructive and cardiovascular surgery. Its commercial portfolio is SimpliDerm, a human acellular dermal matrix sold in its Women's Health segment, plus ProxiCor, VasCure and Tyke in its Cardiovascular segment, sold directly to healthcare facilities through independent sales agents. Its lead development programs are NXT-41 and NXT-41x, a next-generation biologic matrix and an antibiotic-eluting version of the same matrix.

Revenue drivers

• Women's Health (SimpliDerm) — SimpliDerm is the hADM soft tissue reconstruction product and the primary commercial product in the Women's Health segment; it is supplied under a long-term supply agreement with Berkeley Biologics after the 2023 Orthobiologics divestiture.
• Cardiovascular (ProxiCor, VasCure, Tyke) — A cardiovascular repair portfolio sold through independent sales agents; the porcine SIS-ECM used in these products is supplied by Cook Biotech (now owned by Evergen) under a long-term supply agreement, its sole source.
• Divested CIED Business (historical) — EluPro, CanGaroo, CanGaroo RM and CIED envelope products were sold to Boston Scientific and Cardiac Pacemakers for up to $88.0 million in cash on October 1, 2025, and are reported in discontinued operations.
• Pending SimpliDerm divestiture proceeds — The company states it expects up to $11 million from the SimpliDerm divestiture, comprising $8 million in cash at closing and up to $3 million in contingent technology transfer and commercial milestone payments.

Recent performance

Second quarter 2026 revenue was $2.4 million, down from $3.1 million in Q1 2026 and $3.3 million in each of the two prior quarters. Annual revenue fell from $24.7 million in 2023 to $14.5 million in 2024 and $12.3 million in 2025, reflecting divested businesses. Fiscal 2025 net income was $53.4 million, driven by the CIED sale, compared with a $53.9 million net loss in 2024. Operating cash flow was negative $44.8 million in 2025, versus negative $22.7 million in 2024. At June 30, 2026, Elutia reported total assets of $43.6 million, total liabilities of $27.9 million, shareholder equity of $15.7 million and cash of $19.9 million.

Strategy

Following the October 2025 CIED sale, Elutia is focused on advancing its drug-eluting biomatrix platform, led by NXT-41 (a next-generation biologic matrix) and NXT-41x (the same matrix with local antibiotic delivery). The company reports it has secured up to $26 million without an equity offering—a $15 million credit facility and up to $11 million from the SimpliDerm divestiture—to fund through anticipated NXT-41x clearance and first full commercial launch in 2028. It also expects the full $8 million held in escrow from the 2025 BioEnvelope divestiture in the fourth quarter of 2026. Development and manufacturing take place at its leased Gaithersburg, Maryland site, with a corporate office in San Diego.

Risks

• Dependence on unapproved pipeline — The company states its future results now depend on the Women's Health and Cardiovascular businesses and on successful development of NXT-41 and NXT-41x, which have not yet received FDA clearance.
• Single-source suppliers — SimpliDerm is supplied solely by Berkeley and the Cardiovascular porcine SIS-ECM solely by Cook/Evergen, and the company states it cannot guarantee that a supply interruption would not harm the business.
• Declining commercial revenue — Quarterly revenue fell to $2.4 million in Q2 2026 from $3.3 million in late 2025, and annual revenue declined from $24.7 million in 2023 to $12.3 million in 2025.
• Ongoing cash use and financing needs — Operating cash flow was negative $44.8 million in 2025, and funding for the NXT-41x launch depends on a credit facility and divestiture proceeds, including contingent milestone payments not yet received.

Outlook

Management says it is funded through the anticipated clearance and full commercial launch of NXT-41x without an equity offering. It expects an FDA clearance decision for NXT-41 in the fourth quarter of 2026 and for NXT-41x in the first half of 2027, with first full commercial launch in 2028. The company also expects release of the full $8 million escrow from the 2025 BioEnvelope divestiture in the fourth quarter of 2026. It cites an independent blinded survey of 50 plastic surgeons in which 96% expressed interest in adopting NXT-41x and 92% said they would support it at their hospital value analysis committee.